Clinical Studies

      Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article

      First posted
      Dec 22, 2008
      Identifier
      NCT00812279
      Publication Site URL
      Topic
      Official Title

      A Controlled, Randomised, Open-Label, 3-Arm Parallel Single-centre Confinement Study to Investigate Exposure to Selected Smoke Constituents in Smokers Switching From Conventional Cigarettes to SMAR Cigarettes for 5 Days

      Brief Summary

      The overall purpose of this clinical study conducted in confinement under well-defined conditions is to obtain initial data on the levels of human body exposure to selected smoked constituents of the SMAR cigarette.The main objective of this study is to compare the biomarkers of exposure to cigarette smoke constituents in smokers switching to SMAR and to biomarkers in smokers of conventional cigarettes (CC). The biomarkers of exposure will be measured in blood and urine samples collected from the subjects. Moreover, the biomarkers in subjects smoking conventional or SMAR cigarettes will be compared with those biomarkers in smokers who stop smoking for 5 days. The short term safety of this new product will also be evaluated.

      Summary

      Recruitment: Completed

      Study Results: No Results Available

      Enrollment: 112

      Study Type: Interventional

      Other IDs: YVD-CS01-EU

      Related Publications

      Meta-analysis of the effects of smoking and smoking cessation on triglyceride levels

      Clinical

      Smoking and apolipoprotein levels: A meta-analysis of published data

      Clinical

      Effect of switching from cigarette smoking to the use of the tobacco heating system on periodontitis treatment outcome: Periodontal parameter results from a multicenter Japanese study

      Clinical

      Effects of switching to a heat-not-burn tobacco product on biologically relevant biomarkers to assess a candidate Modified Risk Tobacco Product: A randomized trial

      Clinical

      Tobacco Heating System in mild to moderate chronic obstructive pulmonary disease subjects: An exploratory analysis

      Clinical

      Assessing the Effects of Switching from Cigarettes to the Tobacco Heating System Relative to Smoking Cessation on Biomarkers of Potential Harm – Additional Evidence on the Potential to Reduce the Risk of Smoking-related Diseases

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.